<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949103</url>
  </required_header>
  <id_info>
    <org_study_id>0104</org_study_id>
    <nct_id>NCT01949103</nct_id>
  </id_info>
  <brief_title>TD-1607 MAD Study in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double−Blind, Placebo−Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD−1607, a Glycopeptide−Cephalosporin Heterodimer Antibiotic, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma Antibiotics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TD-1607, administered intravenously as multiple ascending doses, will be investigated in
      healthy subjects to assess its tolerability, safety, and pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>17 days</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vdss</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted in urine (Ae</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction eliminated in urine (fe)</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>17 Days</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Infections</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>TD-1607 or placebo (Dose1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1607 or placebo administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1607 or placebo (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1607 or placebo administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1607 or placebo (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1607 or placebo administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1607 or placebo (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1607 or placebo administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1607 or placebo (Dose 5) [Optional]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1607 or placebo administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1607 or placebo (Dose 6) [Optional]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-1607 or placebo administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1607</intervention_name>
    <arm_group_label>TD-1607 or placebo (Dose1)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 2)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 3)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 4)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 5) [Optional]</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 6) [Optional]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>TD-1607 or placebo (Dose1)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 2)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 3)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 4)</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 5) [Optional]</arm_group_label>
    <arm_group_label>TD-1607 or placebo (Dose 6) [Optional]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a healthy nonsmoking male or a female (of non-childbearing potential) and
             18 to 55 years old, inclusive, at Screening.

          -  Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least
             50 kg.

        Subject has no clinically significant abnormalities in the results of laboratory
        evaluations at Screening and Day -1.

        Exclusion Criteria:

          -  Subject has evidence or history of clinically significant, relevant hematological,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
             neurological, or allergic disease (except for untreated, asymptomatic seasonal
             allergies at time of dosing).

          -  Subject has a history of allergies or hypersensitivities to glycopeptide (e.g.,
             vancomycin) or beta-lactam (e.g., penicillin or cephalosporin) antibiotics.

          -  Subject has participated in another clinical trial of an investigational drug (or
             medical device) within 60 days (or 5 half-lives, whichever is longer) prior to
             Screening or is currently participating in another trial of an investigational drug
             (or medical device).

          -  Subject has previously participated in a trial for TD-1607.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD, Phase 1 Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

